Susan Kelly

4 days ago | medtechdive.com | Susan Kelly

This audio is auto-generated. Please let us know if you have feedback. Johnson & Johnson CFO Joseph Wolk, at the Bernstein investor conference last week, tempered the company's expectation that it would suffer a $400 million tariff impact this year. Wolk gave the update after the U.S. and China reached a temporary agreement to pause escalating tariff rates between the two countries for 90 days.

5 days ago | medtechdive.com | Susan Kelly

This audio is auto-generated. Please let us know if you have feedback. The Food and Drug Administration did not appeal a recent U.S. District Court decision that set aside the agency’s final rule aimed at increasing its authority over laboratory developed tests, according to two lab industry groups. The 60-day window for the FDA to appeal the ruling by the U.S. District Court for the Eastern District of Texas expired over the weekend.

1 week ago | medtechdive.com | Susan Kelly

This audio is auto-generated. Please let us know if you have feedback. Abbott said Tuesday it received Food and Drug Administration approval for the Tendyne transcatheter mitral valve replacement system to treat calcium buildup in the ring that supports the heart valve. The device is available for patients with severe mitral annular calcification who are not candidates for open heart surgery or transcatheter mitral valve repair.

1 week ago | medtechdive.com | Susan Kelly

This audio is auto-generated. Please let us know if you have feedback. Name: Kevin ThornalNew title: Group president for global businesses and the Americas, Zimmer BiometPrevious title: President and CEO, NevroZimmer Biomet named Kevin Thornal to the newly created position of group president for global businesses and the Americas, effective July 1, the orthopedics device maker said Tuesday.

2 weeks ago | medtechdive.com | Susan Kelly

This audio is auto-generated. Please let us know if you have feedback. Medical device makers are leaning on their global manufacturing footprints to shift production and inventory as they navigate fluid tariff policies. Large medtech manufacturers are avoiding potentially costly strategies such as reducing sales staff or investments in research and development, analysts said in interviews with MedTech Dive. Price increases are a last resort.